Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | SERPINH1 | P50454 | 2/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30605805 | 0.87 | MAPT (0.91) | MAPTNPSR1TDP1MAPK1KDM4E | |
| SCHEMBL2672236 | 0.87 | MAPT (0.91) | MAPTNPSR1TDP1MAPK1KDM4E | |
| SCHEMBL12827637 | 0.81 | MAPT (0.46) | MAPTNPSR1TDP1MAPK1KDM4E | |
| SCHEMBL1258527 | 0.72 | MAPK1 (1.00) | MAPTNPSR1TDP1MAPK1KDM4E | |
| SCHEMBL10439991 | 0.67 | MAPT (0.47) | MAPTNPSR1TDP1MAPK1KDM4E | |
| SCHEMBL29045042 | 0.66 | TDP1 (0.59) | MAPTNPSR1TDP1MAPK1KDM4E | |
| SCHEMBL10590749 | 0.66 | TDP1 (0.43) | MAPTNPSR1TDP1MAPK1KDM4E | |
| SCHEMBL31070256 | 0.65 | PTGS2 (0.44) | MAPTTDP1ALDH1A1HPGDSERPINH1 | |
| SCHEMBL29045032 | 0.65 | MAPT (0.66) | MAPTNPSR1TDP1MAPK1KDM4E | |
| SCHEMBL4725978 | 0.65 | MAPK1 (0.66) | MAPTNPSR1TDP1MAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071142-A1 | IDENTIFICATION AND USE OF SMALL MOLECULES TO MODULATE TRANSCRIPTION FACTOR FUNCTION AND TO TREAT TRANSCRIPTION FACTOR ASSOCIATED DISEASES | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071142-A1 | IDENTIFICATION AND USE OF SMALL MOLECULES TO MODULATE TRANSCRIPTION FACTOR FUNCTION AND TO TREAT TRANSCRIPTION FACTOR ASSOCIATED DISEASES | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071142-A1 | IDENTIFICATION AND USE OF SMALL MOLECULES TO MODULATE TRANSCRIPTION FACTOR FUNCTION AND TO TREAT TRANSCRIPTION FACTOR ASSOCIATED DISEASES | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2011-03-24 | — | — | US | disclosed |
| WO-2011014299-A2 | IDENTIFICATION AND USE OF SMALL MOLECULES TO MODULATE TRANSCRIPTION FACTOR FUNCTION AND TO TREAT TRANSCRIPTION FACTOR ASSOCIATED DISEASES | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2011-02-03 | — | — | WO | disclosed |
| US-20100120754-A1 | IDENTIFICATION AND USE OF SMALL MOLECULES TO MODULATE TRANSCRIPTION FACTOR FUNCTION AND TO TREAT TRANSCRIPTION FACTOR ASSOCIATED DISEASES | OETTGEN PETER | 2010-05-13 | — | — | US | disclosed |
| WO-2008066672-A2 | IDENTIFICATION AND USE OF SMALL MOLECULES TO MODULATE TRANSCRIPTION FACTOR FUNCTION AND TO TREAT TRANSCRIPTION FACTOR ASSOCIATED DISEASES | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120754-A1 | IDENTIFICATION AND USE OF SMALL MOLECULES TO MODULATE TRANSCRIPTION FACTOR FUNCTION AND TO TREAT TRANSCRIPTION FACTOR ASSOCIATED DISEASES | TEAD1, CREBBP, TEAD2 | MAPT 3224/4885NPSR1 3985/4885TDP1 1450/4885 |
| US-20110071142-A1 | IDENTIFICATION AND USE OF SMALL MOLECULES TO MODULATE TRANSCRIPTION FACTOR FUNCTION AND TO TREAT TRANSCRIPTION FACTOR ASSOCIATED DISEASES | CREBBP, TEAD1, SREBF1 | MAPT 3850/4885NPSR1 3746/4885TDP1 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.